Elias Jabbour, MD

Articles

Dr Jabbour on the Role of Bosutinb as a Therapeutic Option for TKI-Pretreated CML

October 8th 2024

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

August 29th 2024

The key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.

Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting

August 29th 2024

Key opinion leaders address the availability of brexucabtagene autoleucel (brexu-cel) at their institutions and outline procedures for ensuring risk evaluation and mitigation strategy compliance and comprehensive training across multidisciplinary teams.

Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

August 23rd 2024

Acute lymphoblastic leukemia specialists explore resources and strategies to address the logistical hurdles of CAR-T therapy implementation, while also examining patient support programs designed to enhance treatment accessibility and adherence.

Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

August 23rd 2024

Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.

Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

August 15th 2024

The panel explores laboratory parameters routinely monitored for CRS and ICANS, including monitoring frequency, and discusses prophylactic measures and safety management strategies employed to address these complications in CAR-T therapy.

Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

August 15th 2024

Experts evaluate the frequency of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T therapy, comparing their incidence to that observed with other immunotherapies such as bispecific antibodies.

Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

August 8th 2024

The panel examines their strategies for consolidation or maintenance treatment following CAR T-cell therapy, while also considering whether CAR T-cell therapy can function as a standalone treatment modality.

Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

August 8th 2024

Medical experts specializing in acute lymphoblastic leukemia explore emerging trends and potential future developments for CAR T-cell therapy in treating relapsed or refractory B-cell ALL.

Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

August 1st 2024

The panel explores the potential impact of obecabtagene autoleucel on the treatment landscape and decision-making process for acute lymphoblastic leukemia, contingent upon its FDA approval.

Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

August 1st 2024

A medical expert reviews the FELIX study, highlighting its key findings and characteristics while comparing and contrasting it with the ZUMA-3 trial in the context of CAR T-cell therapy for acute lymphoblastic leukemia.

Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

July 25th 2024

The acute lymphoblastic leukemia experts analyze the sequencing of CAR T-cell therapy for patients with and without prior blinatumomab exposure, addressing potential concerns associated with using blinatumomab before CAR T-cell treatment.

Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

July 25th 2024

Medical experts examine the importance of bridging therapies preceding CAR T-cell infusion, addressing their frequency of use and preferred therapeutic agents for this purpose.

Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

July 18th 2024

The panel evaluates key patient characteristics and clinical factors influencing the decision to recommend CAR T-cell therapy as a treatment option in relapsed or refractory acute lymphoblastic leukemia.

Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

July 18th 2024

A medical expert elaborates on the therapeutic role of brexucabtagene autoleucel in the management of relapsed or refractory B-cell acute lymphoblastic leukemia.

Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

July 11th 2024

The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.

Overview of Available Treatment Options in R/R B-cell ALL

July 11th 2024

The panelists explore therapeutic strategies for adult patients diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia.

Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment

July 4th 2024

Medical experts outline the typical timeline for CAR T-cell therapy, encompassing the stages from initial cell collection through manufacturing to final patient infusion.

Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

July 4th 2024

Key opinion leaders succinctly compare the dosing and lymphodepletion protocols for Brexucabtagene autoleucel, Tisagenlecleucel, and Obecabtagene autoleucel.

CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

June 27th 2024

Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).